To determine whether the effects of KPT‐330 and KPT‐8602 on DNA damage, c‐Myc and DDR proteins also occur in primary AML patient samples, we treated primary AML patient samples AML#237 and AML#213 with KPT‐330 and KPT‐8602 for 8 h. This evidence concerns the gene DDR1 and acute myeloid leukemia.